The NAMPT inhibitor market is projected to experience a substantial growth with a compound annual growth rate (CAGR) of 15% during the forecast period, driven by the escalating burden of cancer patients. A study published in the American Cancer Society Journal has estimated that by 2040, the number of cancer cases will surpass 28 million, reflecting a cumulative growth of nearly 47% since 2020. This persistent rise in cancer patient numbers places a significant strain on both financial and healthcare resources. Notably, the annual expenditure related to cancer care in the US alone exceeds USD 200 billion.

As the majority of current cancer treatment options, particularly for late-stage cancers, are deemed inadequate, there is a pressing demand for highly effective therapeutics. Over time, numerous research studies have revealed that NAMPT (Nicotinamide Phosphoribosyl Transferase) can disrupt the metabolism of NAD+, which serves as the fuel for tumor cells. This concept has spurred extensive research into the development of novel and efficacious drug candidates, namely NAMPT inhibitors. NAMPT inhibitors are under evaluation for a wide range of indications, with a primary focus on oncological disorders. Encouraging research outcomes have garnered significant attention from private and public investors, resulting in investments exceeding USD 650 million since 2018. Fueled by increasing R&D activities, promising clinical data, and substantial financial support, the NAMPT inhibitor market is poised for remarkable growth in the forecast period.

Key Market Segments
Type of Molecule
? Small Molecules
? Biologics

Type of Therapeutic Area
? Oncological Disorders
? Respiratory Disorders

Type of Indication
? Non-Hodgkin Lymphoma
? Hodgkin Lymphoma
? Acute Respiratory Distress Syndrome
? Acute Myeloid Leukemia

Route of Administration
? Oral
? Intravenous

Line of Treatment
? First Line
? Second Line

Geographical Regions
? North America
? Europe
? Asia-Pacific
? Rest of the World

Research Coverage:
? The report studies the NAMPT inhibitor market by type of molecule, therapeutic area, indication, route of administration, line of treatment and key geographical regions
? The report analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth.
? The report assesses the potential advantages and obstacles within the market for those involved and offers information on the competitive environment for top players in the market.
? The report forecasts the revenue of market segments with respect to major regions.
? A comprehensive overview of the current market landscape for NAMPT targeting drug candidates currently under research in pre-clinical and clinical studies.
? A detailed analysis of recent partnerships and collaborations among stakeholders in the NAMPT inhibitor domain since 2022.
? An insightful analysis of recent funding instances reported by players in the NAMPT inhibitor market, including information on the year of funding, the amount received, and the type of funding.
? An in-depth analysis of various grants received by players in this field since 2022, based on the year of the award, amount awarded, funding institute, activity code, focus area, recipient organizations, support period, type of grant application, and prominent program officers.
? An insightful company competitiveness analysis of NAMPT inhibitor therapy developers based on various relevant parameters, such as portfolio strength, partnership strength and funding strength.
? Comprehensive profiles of prominent players engaged in the development of NAMPT inhibitors, providing an overview of the company, along with information on financials, product portfolio, patent portfolio, recent developments, and an informed future outlook.
? A detailed analysis of several peer-reviewed scientific articles related to research on NAMPT inhibitors over the last 12 years, based on parameters such as the year of publication, type of publication, and popular keywords.
? An analysis of global events attended by industry players, considering various parameters such as the year of the event, event platform, type of event, leading presenters (in terms of the number of participations), and leading players (in terms of the number of participations).
? An analysis of prevalent and emerging trends related to NAMPT inhibitors as represented on the social media platform, Twitter. This analysis considers parameters like the year of the tweet, top users, and emerging focus areas.
? An in-depth analysis focused on NAMPT inhibitors that failed to progress to later stages of clinical development, considering various relevant parameters, such as the phase of discontinuation, target indication, route of administration, and type of molecule.
? A proprietary analysis of various competitive strategies that can be implemented by drug developers in the NAMPT inhibitor market to expedite the FDA approval process for their proprietary products. This analysis includes information on various parameters, such as clinical evidence, awards/grants, research findings, partnerships, other financial support received, and more.

Key Benefits of Buying this Report
? The report offers market leaders and newcomers valuable insights into revenue estimations for both the overall market and its sub-segments.
? Stakeholders can utilize the report to enhance their understanding of the competitive landscape, allowing for improved business positioning and more effective go-to-market strategies.
? The report provides stakeholders with a pulse on the container closure integrity testing market, furnishing them with essential information on significant market drivers, barriers, opportunities, and challenges.
? You will get access to complimentary PPT insights and excel data packs / dynamic dashboards to easily navigate through complex analyses / charts.

Key Market Companies
? Antengene Therapeutics
? Aqualung Therapeutics
? Karyopharm Therapeutics
? OncoTartis
? Onxeo